New injection aims to tame chronic hepatitis b
NCT ID NCT07673068
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This early-stage trial tests an injection called TVAX-028 in adults with chronic hepatitis B. The study checks if the drug is safe and how the body processes it. Participants receive either TVAX-028 with an adjuvant or the adjuvant alone, at different dose levels. The goal is to gather initial safety data before larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TVAX-028 injection (with adjuvant)
- What this could lead to
- If safe and effective, this could lead to a new treatment option for chronic hepatitis B, potentially helping control the virus long-term.
- What could go wrong
- This is an early Phase 1 trial with only 32 participants, focused on safety. It is too soon to know if TVAX-028 will work, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo aims to cure chronic hepatitis b
- Zambia study tracks hepatitis b outcomes in hundreds of patients
- New drug cocktail shows promise for liver cancer in hepatitis b patients
- New shot aims to tame hepatitis b virus
- New hepatitis b drug shows early promise in small trial
- Massive french study to track virus effects on pregnant women and kids for 7 years